Pay Day For Reata As Bardoxolone Progresses For Kidney Disease In Japan
Executive Summary
Reata reaps benefit from 2009 licensing deal with Kyowa Hakko Kirin for bardoxolone as transcription factor activator moves into pivotal study for kidney disease in Japan.